FDA Guidance & Compliance Intelligence
ERMA is designed to help life sciences teams navigate the evolving landscape of FDA promotional regulations with greater confidence and control. At its core, ERMA continuously validates marketing and promotional materials against the latest FDA guidance, helping teams identify potential compliance risks before materials enter or progress through the MLR review process.
By analyzing content for claims, context, and supporting evidence, the platform flags areas that may require stronger substantiation or regulatory review, helping reduce the likelihood of OPDP warning or untitled letters.
Beyond referencing FDA regulations alone, ERMA also maintains a living knowledge base of FDA enforcement actions, guidance updates, and precedent-setting letters issued to pharmaceutical and biotech companies. This provides additional regulatory context, allowing teams to understand how the FDA has interpreted and enforced promotional standards in real-world scenarios.
In addition to validating materials against FDA guidance, the platform gives organizations the autonomy to establish their own internal compliance rules and guardrails. Teams can configure guidance frameworks that reflect their internal SOPs, incorporate learnings from previous regulatory violations, or apply company-specific standards that go beyond FDA baseline requirements.
This flexibility ensures ERMA adapts to the way organizations operate rather than forcing teams into rigid compliance structures. Regulatory, medical, and legal teams can refine and evolve their internal rules over time, creating a dynamic compliance environment that strengthens institutional knowledge and improves consistency across materials, brands, and review cycles.
- Continuous validation against the latest FDA promotional guidance
- Living knowledge base of FDA enforcement actions and precedent-setting letters
- Configurable internal compliance rules aligned to company SOPs and risk tolerance
- Dynamic rules that evolve with regulatory feedback and organizational learnings
The result is a smarter, more flexible approach to promotional compliance, one that combines FDA regulatory intelligence with the practical realities of how life sciences organizations manage risk internally.